Table 3.
Oe of PFSMIA
| Case | Travel | Known vaccinations | Days post first symptom of sera | Previous diagnostic evidence | Dengue typea | Main serological reactions (with activity changes), PFSMIA (steps 6 and 7)b | Case judgement, PFSMIA (step 8)c | Concordance |
|---|---|---|---|---|---|---|---|---|
| ZIKV disease | ||||||||
| Z1 | Brazil, Sao Paulo | 20,37,249 | IgM | M: ZIKV (zik §3/1 0.00). G: ZIKV, TBEV_vacc (zik !2/1 1.57) | Primary: ZIKV, Previous: DENV?, TBEVACC? | OK | ||
| Z2 | Brazil Sao, Paulo | 20,37.249 | IgM | M: ZIKV? (zik §2/1 0.23) G: TBEV_vacc? | Primary: ZIKV Previous: DENV | OK | ||
| Z3 | Colombia | 10,15,66,207,233 | IgM | M: ZIKV (zik §4/1 0.01), G: (zik !4/1 12) | Primary: ZIKV | OK | ||
| Z4 | Martinique | 11,16,36 | IgM | M: ZIKV (zik !2/1 4.0, zik §3/2 0.48), G: (zik !3/1 > 100) | Primary: ZIKV | OK | ||
| Z5 | Martinique | 2,7,27 | IgM | M: (zik !2/1 21, zik §3/2 0.37), G: (zik !3/1 > 100) | Primary: ZIKV | OK | ||
| Z6 | Mesoamerica | TBEV | 114 | PCR/s, PCR/u, IgM, etc. | G: ZIKV | Previous: ZIKV | OK | |
| Z51 | Colombia | 66,119,176,211,289, 309, 365, 408 | IgM, NT | M: ZIKV? (zik §6/1 0.00), G: ZIKV (zik §8/2 0.50) | Primary: ZIKV | OK | ||
| Z52 | Brazil, Sao Paolo | TBEV 1994 | 39,248,435 | IgM | M: ZIKV? (zik §3/1 0.06), G: ZIKV, TBEV_vacc (zik §3/1 0.39, tbevacc §3/1 0.36) | Primary: ZIKV, Previous: TBEVACC? | OK | |
| Z53 | Brazil, Sao Paolo | TBEV 1994 | 403,246, 427 | IgM | M: ZIKV, G: ZIKV, TBEV_vacc, (tbevacc §3/1 0.49) | Primary: ZIKV, Previous: TBEVACC? | OK | |
| Z54 | Martinique | 12,17,38,53,116 | PCR/u, IgM | M: ZIKV, YFV? (zik §4/1 0.04, yfv §2/1 0.04) G: (zik !3/1 5.8) | Primary: ZIKV, YFV | OK | ||
| Z55 | Martinique | 3,8,28,45,101 | PCR/u, IgM, NT | M: ZIKV (zik §4/1 0.00), G: (zik !4/1 7.6) | Primary: ZIKV, DENV? | OK | ||
| Z56 | Haiti, Porte au Prince | YFV 2011, TBEV 2003 | 20 | PCR/u, NT | M: ZIKV, G: ZIKV, TBEV_vacc, YFV? | Primary: ZIKV, Previous: TBEVACC | OK | |
| Z57 | The Netherlands, ABC islands | YFV | 1,8,23,56 | PCR/u, IgM | M: ZIKV, YFV? (zik §3/1 0.19). G: ZIKV, YFV? (zik !2/1 1.94, yfv §3/2 0.35) | Primary: ZIKV, TBEVACC? | OK | |
| DENV fever | ||||||||
| D1 | Myanmar | 6,42 | Ag | DENV2 | M: (den !2/1 5.3) | Primary: DENV | OK | |
| D2 | Thailand | 14,32 | Ag | DENV3 | M: (den !2/1 > 100, yfv !2/1 > 100), G: TBEV_vacc? (den !2/1 11, yfv !2/1> 100, tbevacc !2/1 2.3) | Primary: YFV, DENV | OK? | |
| D3 | Thailand | 14,32 | Ag | DENV1 | G: (den !2/1 8.2) | Primary: DENV | OK | |
| D30 | Thailand | 11 | Ag | DENV3 | M: DENV | Primary: DENV | OK | |
| D31 | Thailand | 9 | Ag | DENV1 | M: DENV G: TBEV_vacc? | Primary: DENV | OK | |
| D32 | Thailand | 40 | Ag | DENV1 | M: DENV G: TBEV_vacc? | Primary: DENV | OK | |
| D35 | Curacao | 35 | Ag | DENV3 | M: DENV G: DENV?, TBEV_vacc? | Primary: DENV | OK | |
| D38 | Thailand | 47 | Ag | DENV4 | M: DENV G: DENV, TBEV_vacc? | Primary: DENV | OK | |
| D39 | Philippines | U | Ag | DENV1 | M: DENV G: TBEV_vacc | Primary: DENV, Previous: TBEVACC? | OK | |
| D40 | Thailand | U | Ag | DENV1 | M: DENV, TBEV_vacc? G: DENV | Primary: DENV | OK | |
| D43 | Thailand | 13 | Ag | DENV1 | M: DENV | Primary: DENV | OK | |
| D45 | Bolivia | 14 | Ag | DENV4 | M: DENV, TBEV_vacc? G: TBEV_vacc? | Primary: DENV, TBEVACC? | OK | |
| D46 | Costa Rica | U | Ag | DENV2 | M: DENV G: TBEV_vacc? | Primary: DENV | OK | |
| D51 | Sri Lanka | 4,18,44,50,206,244,339 | PCR/s, IgM, Ag | DENV1 | M: DENV(den !2/1 4.9,den §5/2 0.13) G: DENV (den !3/1 38, den §6/3 0.41) | Primary: DENV | OK | |
| D52 | Bali | 14 | PCR/s, Ag | DENV1 | M: DENV G: TBEV_vacc | Primary: DENV, Previous: TBEVACC | OK | |
| D53 | India, New Delhi | 14 | PCR/s, IgM | DENV1 | M: DENV G: DENV, TBEV_vacc? | Primary: DENV | OK | |
| D54 | U | U | IgM | DENV1 | M: DENV, G: DENV | Primary: DENV | OK | |
| D55 | Thailand | 10,440 | IgM | DENV1 | M: DENV, TBEV_vacc? (den §3/1 0.22, yfv !2/1 4.4, tbevacc §2/1 0.36 .00) G: TBEV_vacc (den !3/2 3.7) | Primary: DENV, TBEVACC, YFV? | OK | |
| D56 | Thailand | 21,262,634, | PCR/s, IgM | DENV2 | M: DENV, ZIKV (den §3/1 0.19) G: DENV (den !2/1 3.0) | Primary: DENV, ZIKV? | OK? | |
| D57 | Brazil | 10,40 | IgM | DENV2 | M: DENV, G: DENV, YFV?, USUV? (usu §2/1 0.40) | Primary: DENV, Previous: YFV? | OK | |
| D58 | Thailand | U | IgM | DENV2 | M: DENV (den §3/1 0.11 .00) G: DENV, TBEV_vacc (den !2/1 2.6) | Primary: DENV | OK | |
| D59 | U | U | Ag | DENV2 | G: DENV, TBEV_vacc? (den §3/1 0.34, tbevacc §3/1 0.34) | Previous: DENV, TBEVACC? | OK | |
| D60 | U | U | IgM | DENV2 | G: DENV | Previous: DENV | OK | |
| D61 | Thailand | U | Ag, IgM | DENV3 | M: DENV (den §3/2 0.30) G: (den !3/1 33) | Primary: DENV | OK | |
| D62 | Malaysia, Bali | TBEV as child | 1,5,19,52 | PCR/s, Ag, IgM | DENV3 | M: YFV?, DENV G: TBEV_inf (den !3/1 3.9) | Primary: DENV, YFV?, Previous: TBEINF | OK? |
| D63 | U | 4 | PCR/s, Ag, IgM | DENV4 | M: DENV | Primary: DENV | OK | |
| D64 | U | 6 | PCR/s, Ag, IgM | DENV2 | M: DENV G: TBEV_vacc | Primary: DENV, Previous: TBEVACC? | OK | |
| D65 | U | 7 | PCR/s, Ag, IgM | DENV2 | M: DENV G: TBEV_vacc | Primary: DENV, Previous: TBEVACC? | OK | |
| D66 | U | 16 | PCR/s, Ag | DENV4 | M: DENV G: DENV, USUV? | Primary: DENV | OK | |
| D67 | U | 6 | PCR/s, Ag, IgM | DENV3 | M: DENV | Primary: DENV | OK | |
| D68 | U | 4 | PCR/s, Ag, IgM | DENV4 | M: DENV, ZIKV G: TBEV_vacc | Primary: DENV, ZIKV?, Previous: TBEVACC | OK | |
| D69 | U | 11 | PCR/s, Ag, IgM | DENV2 | M: DENV? G: DENV | Primary: DENV | OK | |
| D70 | U | 8 | PCR/s, Ag, IgM | DENV1 | M: DENV G: DENV | Primary: DENV | OK | |
| D71 | U | 12 | PCR/s, Ag, IgM | DENV2 | M: DENV, G: TBEV_vacc | Primary: DENV, Previous: TBEVACC | OK | |
| D72 | U | U | PCR/s, Ag, IgM | DENV3.4 | M: DENV, G: TBEV_vacc, DENV | Primary: DENV, Previous: TBEVACC | OK | |
| D73 | U | 8 | PCR/s, Ag, IgM | DENV1 | M: DENV G: TBEV_vacc, DENV? | Primary: DENV, Previous: TBEVACC | OK | |
| D74 | U | 12 | PCR/s, Ag, IgM | DENV2 | M: DENV G: TBEV_vacc? | Primary: DENV | OK | |
PCR/u PCR in urine, PCR/s PCR in serum, Ag DENV antigen detection, NT neutralization test, U unknown
aSamples from patient D72 were positive for both DENV3 and DENV4
bThis column summarizes all reactions of sera belonging to the patient at program steps 6 and 7 of Table 1. M IgM, G IgG. Activity changes are within brackets. ! = rise, § = decline, followed by High Serum nr/Low Serum nr and ratio. Abbreviations: zik = ZIKV, Zika, den = DENV, Dengue, usu = USUV, Usutu, TBE_vacc, tbevacc = TBE vaccination, TBE_inf = TBE infection
cThis column contains results of program step 8 of Table 1